MarginsXMarginsX
Home › Markets › Health Care › KPRX

Kiora Pharmaceuticals Inc. (KPRX)

KPRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9820
-20.16% on the day
Market cap
$4.3M
Nano cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$10.8M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/0001372514-26-000024-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKPRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001372514
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$10.8M
Operating income-$12.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$8.7M
Total assets$24.3M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
8.6 months
$5.6M cash at September 30, 2026
Share count, 1 year
+20.3%
2025-11-05 to 2026-11-10 · +417.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The factors described above have caused management to determine there is substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$5.6M cash; operating cash flow -$1.9M a quarter.Report 2026-09-30
Shares outstanding4,424,387 (2026-11-10); 3,677,935 a year earlier; 7,689,240 three years earlier. 3y figure adjusted for splits (1-for-9 overall).Cover page 2026-11-10
Reverse splits, 3 years1; latest 1-for-9 on 2024-06-11Source 2024-06-11
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorHaskell & White LLP, Irvine, California, United StatesPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.0M-$1.7M-$558K$5.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$2.1M-$1.9M$7.1MNo debt tagsNeeds four quarters10-Q 2026-08-07
Q1 2026
2026-03-31
Not filed-$2.4M-$3.2M$11.0MNo debt tagsNeeds four quarters10-Q 2026-05-08
Q4 2025
2025-12-31
$0-$6.5M-$2.2M$8.7MNo debt tags$010-K 2026-03-25
Q3 2025
2025-09-30
$0$27K-$1.3M$5.5MNo debt tags$010-Q 2026-11-12
Q2 2025
2025-06-30
$0-$2.2M-$3.8M$1.0MNo debt tags$010-Q 2025-08-08
Q1 2025
2025-03-31
$0-$2.2M-$2.7M$3.8MNo debt tags$20K10-Q 2025-05-09
Q4 2024
2024-12-31
$0-$4.2M-$2.3M$3.8MNo debt tags$16.0M10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-05-28
Latest annual report10-K2026-03-25
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 929 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.6%
1 month-50.2%
3 months-52.5%
Year to date-37.6%
1 year-44.0%
From 52-week high-57.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BGMSBio Green Med Solution Inc.$0.6502+1.55%$4.3M
NCNANuCana plc American Depositary Share$0.8631-7.46%$4.4M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
TRAWTraws Pharma Inc.$0.2600+3.59%$4.0M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
PULMPulmatrix Inc.$1.33+2.31%$4.9M
IMNNImunon Inc.$0.5940-5.56%$3.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier